Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 5/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.41 |
| ▸ | GK | P32189 | 1/20 | 0.38 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14378923 | 0.87 | GK (0.47) | P2RY2P2RY4GKPRMT5WDR77 | |
| SCHEMBL14378919 | 0.86 | GK (0.34) | P2RY2P2RY4GKPOLA1P2RY6 | |
| SCHEMBL13005782 | 0.72 | P2RY2 (0.38) | P2RY2P2RY4GKP2RY6P2RY14 | |
| SCHEMBL1738161 | 0.72 | PRMT5 (0.55) | P2RY2P2RY4PRMT5WDR77ADORA2A | |
| SCHEMBL14544364 | 0.72 | PRMT5 (0.55) | P2RY2P2RY4PRMT5WDR77ADORA2A | |
| SCHEMBL14094798 | 0.71 | P2RY2 (0.41) | P2RY2P2RY4GKPOLA1P2RY6 | |
| SCHEMBL14154286 | 0.71 | ADK (0.44) | PRMT5WDR77ADORA3ADORA2AADORA2B | |
| SCHEMBL14782087 | 0.71 | P2RY2 (0.61) | P2RY2P2RY4POLA1PRMT5WDR77 | |
| SCHEMBL1739812 | 0.71 | P2RY2 (0.61) | P2RY2P2RY4POLA1PRMT5WDR77 | |
| SCHEMBL21006619 | 0.70 | P2RY2 (0.63) | P2RY2P2RY4POLA1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598230-B2 | For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | P2RY2 104/4885P2RY4 46/4885GK 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.